Use access key #2 to skip to page content.

portefeuille (99.60)

INSM

Recs

4

June 12, 2011 – Comments (5)

I "recommended" buying a few INSM shares in March 2011 in this post. It might be a good time to sell some of those now. There are currently 910 INSM shares in my "fund" (see here) with break-even of around 1.31 USD.

 



enlarge

5 Comments – Post Your Own

#1) On June 13, 2011 at 4:34 PM, portefeuille (99.60) wrote:

June 10, 2011 - 34th European Cystic Fibrosis Society (ECFS) Conference - A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

Poster #217 (pdf)

Poster #217 Presentation (pdf)

Report this comment
#2) On June 13, 2011 at 4:51 PM, portefeuille (99.60) wrote:

Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections

Report this comment
#3) On June 14, 2011 at 2:31 PM, TheDumbMoney (38.75) wrote:

Portefeuille, I remember you saying at some point that someone on CAPS showed you how to embed images (as opposed to just links) in your blog posts.  I am wondering if you would be so kind as to quickly enlighten me?

Report this comment
#4) On June 14, 2011 at 3:31 PM, portefeuille (99.60) wrote:

#3 It is described in comment #24 here.

Report this comment
#5) On August 02, 2011 at 2:44 PM, portefeuille (99.60) wrote:

It might be a good time to sell some of those now.

It might be a good time to buy them back now. INSM is currently at around $5.86.

Report this comment

Featured Broker Partners


Advertisement